Edward Tate is Professor of Chemical Biology in the Department of Chemistry at Imperial College London, and a Satellite Group Leader at the Francis Crick Institute. He completed his PhD in organic chemistry at the University of Cambridge in the group of Professor Steve Ley. Following postdoctoral research in chemistry and biology on an 1851 Research Fellowship at CNRS Gif sur Yvette and Ecole Polytechnique and the Pasteur Institute in Paris, he moved to Imperial College London on a BBSRC David Phillips Fellowship, where he was promoted to a Chair in 2014.
Professor Tate leads a team of more than 50 scientists working on the design and application of chemical approaches to understand and manipulate living systems, with a particular focus on drug target discovery and validation. He is a Fellow of the Royal Societies of Chemistry (FRSC) and of Biology (FRSB), and Director of Imperial’s Centre for Drug Discovery Science. He received the 2012 Wain Medal, the 2013 MedImmune Protein and Peptide Science Award, the 2014 Norman Heatley Award, and a 2015 Cancer Research UK Programme Foundation Award in recognition of his group’s research in chemical biology and drug discovery.
In 2019, he became the founder and Chief Scientific Officer of Myricx Pharma, a drug discovery spinout from Imperial and the Francis Crick Institute established to develop discoveries made in his labs; his team was awarded the Sir David Cooksey Translation Prize in recognition of this achievement.